Praxis CFO (PRAX) gets 8,800 RSUs, 7,040 options in Form 4 filing

Rhea-AI Filing Summary

Praxis Precision Medicines’ Chief Financial Officer Timothy Edwin Kelly reported new equity awards and a tax-related share withholding. On January 8, 2026, he received 8,800 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on the one-year anniversary of January 8, 2026. That same day he was granted a stock option for 7,040 shares at an exercise price of $294.38 per share, vesting 25% on January 8, 2027 and the remaining 75% in 36 monthly installments, subject to continued service. On January 10, 2026, 1,335 shares of common stock were withheld at $288.45 per share to cover tax obligations tied to earlier RSU vesting. After these transactions, he directly beneficially owned 31,989 common shares and 7,040 stock options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kelly Timothy Edwin

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/08/2026		A(1)		8,800	A	$0	33,324	D
Common Stock	01/10/2026		F(2)		1,335	D	$288.45	31,989	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$294.38	01/08/2026		A		7,040		(3)	01/08/2036	Common Stock	7,040	$0	7,040	D

Explanation of Responses:

1. Mr. Kelly was awarded 8,800 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units vest in equal annual installments over a four-year period beginning on the one-year anniversary of the vesting commencement date of January 8, 2026. The restricted stock units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

2. Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported restricted stock units.

3. The shares underlying this stock option vest over a four-year period, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date.

Remarks:

	/s/ Alex Nemiroff, as Attorney-in-Fact	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Praxis Precision Medicines (PRAX) report for its CFO?

The filing shows that Chief Financial Officer Timothy Edwin Kelly received new equity awards and had shares withheld to pay taxes related to prior restricted stock unit vesting.

How many restricted stock units did the Praxis (PRAX) CFO receive?

He was awarded 8,800 restricted stock units, each representing a contingent right to receive one share of Praxis Precision Medicines common stock.

What are the vesting terms for the Praxis CFO’s new RSU grant?

The 8,800 RSUs vest in equal annual installments over four years, starting on the one-year anniversary of the January 8, 2026 vesting commencement date, and are settled only in common shares.

What stock options were granted to the Praxis Precision Medicines CFO?

He received a stock option for 7,040 shares of common stock with an exercise price of $294.38 per share, reported as acquired on January 8, 2026.

How do the Praxis CFO’s new stock options vest over time?

The 7,040-share option vests over four years: 25% on January 8, 2027, and the remaining 75% in 36 equal monthly installments, subject to his continued service.

Why were 1,335 Praxis shares reported as disposed of by the CFO?

The 1,335 shares of common stock reported with transaction code F on January 10, 2026 were withheld by the issuer to satisfy tax withholding obligations from vesting of previously reported RSUs.

How many Praxis shares and options does the CFO hold after these transactions?

Following the reported transactions, the CFO directly beneficially owned 31,989 shares of common stock and 7,040 stock options of Praxis Precision Medicines.